Posterior Polymorphous Corneal Dystrophy

Comprehensive Clinical Guide: Posterior Polymorphous Corneal Dystrophy (PPCD)

Posterior Polymorphous Corneal Dystrophy (PPCD) represents a rare, often autosomal dominant, spectrum of corneal endothelial disorders. Unlike many other corneal dystrophies that primarily affect the stroma or epithelium, PPCD is characterized by the metaplasia of corneal endothelial cells into an epithelial-like phenotype. This guide provides an exhaustive clinical overview of the condition, intended for ophthalmologists, corneal specialists, and clinical researchers.

1. Introduction and Overview

Posterior Polymorphous Corneal Dystrophy (PPCD) is a bilateral, slowly progressive, and often asymmetric corneal dystrophy. It is categorized under the umbrella of posterior corneal dystrophies, alongside Fuch’s Endothelial Corneal Dystrophy (FECD) and Iridocorneal Endothelial (ICE) syndrome.

While historically considered a static condition, modern clinical observation suggests that while the endothelial changes may be present from birth, they can progress over decades, potentially leading to corneal edema, bullous keratopathy, and secondary glaucoma. The hallmark clinical feature is the presence of vesicular, band-like, or placoid lesions at the level of Descemet’s membrane.

Key Clinical Classification

• ICD-10 Code: H18.59 (Other hereditary corneal dystrophies)
• OMIM Entry: 122000 (PPCD1), 605670 (PPCD2), 609140 (PPCD3)
• Inheritance: Primarily Autosomal Dominant (AD); rare Autosomal Recessive (AR) cases reported.

2. Technical Specifications and Pathophysiology

The pathophysiology of PPCD is rooted in the abnormal development and subsequent metaplasia of the corneal endothelium.

Cellular Mechanisms

In a healthy cornea, the endothelium consists of a single layer of hexagonal cells responsible for maintaining corneal deturgescence via the Na+/K+-ATPase pump. In PPCD, these cells lose their native characteristics and acquire an epithelial-like morphology, including:
1. Multilayering: The endothelium becomes stratified.
2. Desmosome Formation: The cells develop intercellular junctions typical of stratified squamous epithelium.
3. Cytokeratin Expression: The cells begin expressing cytokeratins (e.g., CK19), which are not typically found in healthy corneal endothelium.
4. Basement Membrane Production: These cells secrete an abnormal, thickened posterior collagenous layer (PCL) over the native Descemet’s membrane.

Genetic Etiology

PPCD is genetically heterogeneous, with three primary loci identified:
* PPCD1 (20p11.2): Linked to the VSX1 gene.
* PPCD2 (20q11): Linked to the COL8A2 gene.
* PPCD3 (17q21.33): Linked to the ZEB1 gene (most common cause of PPCD).

3. Clinical Presentation and Staging

Standard Presentation

Patients are frequently asymptomatic in early stages. Symptoms, when they occur, are usually related to corneal edema or elevated intraocular pressure (IOP).
* Asymptomatic: Common in younger patients; incidental finding during routine slit-lamp examination.
* Symptomatic: Photophobia, blurred vision (worse in the morning), and glare.
* Advanced: Painful bullous keratopathy or symptoms of secondary glaucoma.

Clinical Morphology (The "Polymorphous" Spectrum)

Clinical Staging/Grading

While no formal universal staging system exists, clinicians typically use the following framework:
* Stage I (Incidental): Peripheral endothelial changes, visual acuity 20/20.
* Stage II (Progressive): Central involvement, mild stromal haze, occasional visual fluctuation.
* Stage III (Decompensated): Significant corneal edema, bullous keratopathy, reduced visual acuity, potential scarring.
* Stage IV (Complicated): Association with secondary glaucoma, peripheral anterior synechiae (PAS), or iris abnormalities.

4. Differential Diagnosis

Distinguishing PPCD from other endothelial disorders is critical for management.

5. Diagnostic Testing Protocols

A robust diagnostic workup is essential for accurate categorization.

1. Slit-Lamp Biomicroscopy: The gold standard for identifying vesicular, band-like, or placoid lesions.
2. Specular Microscopy: Often reveals loss of hexagonal shape (pleomorphism) and polymegathism. In severe cases, the endothelium may be too thin or irregular to image clearly.
3. Anterior Segment OCT (AS-OCT): Extremely useful for identifying the thickened Descemet’s membrane and the presence of the abnormal posterior collagenous layer.
4. Pachymetry: Essential to monitor for clinical or subclinical corneal edema.
5. Gonioscopy: Mandatory to rule out peripheral anterior synechiae (PAS) and evaluate the angle for secondary glaucoma.

6. Risks, Side Effects, and Contraindications

Management Risks

• Surgical Failure: Penetrating keratoplasty (PKP) or Endothelial Keratoplasty (DSEK/DSAEK) carries a higher risk of recurrence in PPCD compared to other dystrophies, as the abnormal endothelial cells may migrate onto the graft.
• Glaucoma Surgery: Patients with PPCD are at high risk of developing glaucoma due to the migration of endothelial cells into the trabecular meshwork. Traditional glaucoma surgeries may be complicated by the underlying corneal pathology.

Contraindications

• Refractive Surgery: LASIK or PRK is strictly contraindicated in symptomatic patients due to the unstable nature of the endothelium and the risk of inducing rapid decompensation.
• Topical Steroid Overuse: While used for inflammation, chronic use should be monitored to avoid steroid-induced IOP elevation, which is already a risk factor in these patients.

7. Long-Term Prognosis

The prognosis for PPCD is generally good, but it requires lifelong monitoring.
* Visual Stability: Many patients remain stable throughout their lives without requiring surgical intervention.
* Surgical Outcomes: When corneal decompensation occurs, endothelial keratoplasty (DSAEK or DMEK) is the preferred treatment. However, surgeons must be aware that the abnormal endothelial phenotype may eventually affect the graft.
* Glaucoma Monitoring: Because of the association with angle-closure and open-angle glaucoma, annual IOP checks and gonioscopy are mandatory for all patients, even those with clear corneas.

8. Frequently Asked Questions (FAQ)

1. Is PPCD always inherited?

Yes, it is a genetic condition. It is most commonly inherited in an autosomal dominant pattern, meaning a child has a 50% chance of inheriting the condition if one parent is affected.

2. Can PPCD lead to blindness?

In rare, untreated cases, severe corneal edema and secondary glaucoma can lead to significant vision loss. However, with modern corneal transplantation and glaucoma management, total blindness is uncommon.

3. How often should I get my eyes checked if I have PPCD?

If you are asymptomatic, an annual comprehensive eye exam is usually sufficient. If you experience fluctuations in vision or eye pain, you should be seen immediately.

4. Is the condition bilateral?

Yes, PPCD is almost always bilateral, although the severity and the specific morphology of the lesions can be highly asymmetric between the two eyes.

5. Does PPCD affect the iris?

It can. In some patients, the abnormal endothelial cells migrate into the anterior chamber angle and onto the iris, leading to peripheral anterior synechiae (PAS) and corectopia.

6. Can I wear contact lenses with PPCD?

Contact lenses are generally safe unless there is active corneal edema or epithelial bullae. If bullae are present, a bandage contact lens may be used for comfort.

7. What is the difference between PPCD and Fuch’s Dystrophy?

Fuch’s Dystrophy involves the loss of endothelial cells and the formation of central guttata. PPCD involves a metaplasia (change in cell type) of the endothelial cells into epithelial-like cells.

8. Will I need a corneal transplant?

Only a minority of patients with PPCD require a corneal transplant. It is reserved for those who develop significant, vision-limiting corneal edema or bullous keratopathy.

9. Are there any dietary changes to help with PPCD?

There is currently no evidence that diet or nutritional supplements can alter the progression of PPCD.

10. Can I have laser eye surgery (LASIK)?

No. LASIK is contraindicated for patients with PPCD because the corneal endothelium is already compromised, and the procedure can trigger irreversible corneal decompensation.

9. Conclusion

Posterior Polymorphous Corneal Dystrophy is a fascinating, albeit complex, clinical entity. While it is often a benign, incidental finding, the potential for progression, corneal decompensation, and secondary glaucoma necessitates a structured approach to care. By leveraging high-resolution imaging such as AS-OCT and maintaining a high index of suspicion for angle-related complications, clinicians can successfully manage the lifelong ocular health of patients with PPCD.

For the medical professional, the key takeaway is to treat the patient, not just the corneal morphology. Regular monitoring of IOP and central corneal thickness remains the cornerstone of effective management in this patient population.